English: I'm happy to recommit ourselves to driving up standards right across respiratory conditions. We'll have more to say on that in the coming months. There's an interesting project led by a number of people about the possibility for a respiratory innovation centre, which I'm particularly excited about. There could be economic benefits as well as healthcare benefits to that. On asthma, the thing about the report provided by Asthma UK is that, given the size of the sample, I wouldn't quite agree with all of the assertions they make about the comparative nature of care being provided within different nations in the UK, but they are broadly right that we could and should improve on healthcare, both at primary care level as well as at specialist level. We're actually in a position where virtually every general practice participates in the clinical audit for primary care for asthma and COPD. That gives us a good picture of the quality of care delivered locally and areas for improvement. And this is a key area where we're actually improving value, because a number of clinicians have actually looked at the treatments available and they choose what they think is the best value product, which isn't always the highest priced product as well. So, we'll get better value for care, and, of course, in asthma care, we've seen some of the new drugs and treatments available being made available faster here through the new treatment fund, delivering on our manifesto pledge to the people of Wales. So, we recognise we have more to go, but we have a real commitment, and I think really good reasons to be positive about our prospect of improving care outcomes here in Wales in the future.
Welsh: Rwy'n hapus i ailymrwymo i wella safonau ar draws y cyflyrau anadlol. Bydd gennym fwy i'w ddweud am hynny yn y misoedd nesaf. Mae yna brosiect diddorol a arweinir gan nifer o bobl ynglŷn â'r posibilrwydd o ganolfan arloesi anadlol, ac rwy'n arbennig o gyffrous yn ei chylch. Mae'n bosibl y bydd yna fanteision economaidd yn ogystal â manteision gofal iechyd i hynny. Ar asthma, y peth am yr adroddiad a ddarparwyd gan Asthma UK yw, o ystyried maint y sampl, na fuaswn yn cytuno'n llwyr â'r holl honiadau y maent yn eu gwneud ynglŷn â natur gymharol y gofal a ddarperir yng ngwahanol wledydd y DU, ond maent yn gywir at ei gilydd y gallem ac y dylem wella gofal iechyd, ar lefel gofal sylfaenol yn ogystal ag ar lefel arbenigol. Mewn gwirionedd, rydym mewn sefyllfa lle mae bron bob practis cyffredinol yn cymryd rhan yn yr archwiliad clinigol o ofal sylfaenol ar gyfer asthma a chlefyd rhwystrol cronig yr ysgyfaint. Mae hynny'n rhoi darlun da o ansawdd y gofal a ddarperir yn lleol a meysydd ar gyfer gwella. Ac mae hwn yn faes allweddol lle rydym, mewn gwirionedd, yn gwella gwerth, oherwydd mae nifer o glinigwyr wedi edrych ar y triniaethau sydd ar gael ac maent yn dewis y cynnyrch gwerth gorau yn eu barn hwy, ac nid hwnnw yw'r cynnyrch sy'n costio fwyaf bob amser. Felly, byddwn yn cael gwell gwerth am ofal, ac wrth gwrs, mewn perthynas â gofal asthma, rydym wedi gweld rhywfaint o'r cyffuriau a'r triniaethau newydd sydd ar gael yn cael eu cyflwyno'n gynt yma drwy'r gronfa triniaethau newydd, gan gyflawni ein haddewid maniffesto i bobl Cymru. Felly, rydym yn cydnabod bod gennym fwy i'w wneud eto, ond mae gennym ymrwymiad go iawn, a chredaf fod gennym resymau da iawn dros fod yn gadarnhaol ynglŷn â'n gobaith o wella canlyniadau gofal yma yng Nghymru yn y dyfodol.